Chat with us
Research Assistance
Online
  • Please enter your first name.

Middle East & Africa Cancer Immunotherapy Market Size & Outlook

The cancer immunotherapy market in Middle East & Africa is expected to reach a projected revenue of US$ 12,573.9 million by 2033. A compound annual growth rate of 7.5% is expected of Middle East & Africa cancer immunotherapy market from 2026 to 2033.

  • Pharmaceuticals
    • Oncology Drugs
      • Cancer Immunotherapy Market Outlook
Revenue, 2025 (US$M)
$7,047.7
Estimate, 2026 (US$M)
$7,558.2
Forecast, 2033 (US$M)
$12,573.9
CAGR, 2026 - 2033
7.5%
Middle East Africa Cancer Immunotherapy Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Prism AI by Grand View ResearchFree to try

Ask a question about the cancer immunotherapy market

Every figure cited from GVR research

MEA cancer immunotherapy market highlights

  • The MEA cancer immunotherapy market generated a revenue of USD 7,047.7 million in 2025.
  • The market is expected to grow at a CAGR of 7.5% from 2026 to 2033.
  • In terms of segment, monoclonal antibodies was the largest revenue generating product in 2025.
  • Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
  • Country-wise, Kuwait is expected to register the highest CAGR from 2026 to 2033.


MEA data book summary

Market revenue in 2025USD 7,047.7 million
Market revenue in 2033USD 12,573.9 million
Growth rate7.5% (CAGR from 2026 to 2033)
Largest segmentMonoclonal antibodies
Fastest growing segmentOncolytic Viral Therapies and Cancer Vaccines
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines
Key market players worldwidePfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR


Other key industry trends

  • In terms of revenue, MEA region accounted for 4.6% of the global cancer immunotherapy market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 71,890.9 million by 2033.

Rising demand for effective and cost-efficient cancer therapies is one of the major factors contributing to the growth of the cancer immunotherapy drugs market in MEA. Factors such as increase in the need for improved healthcare infrastructure and high burden of diseases, such as cancer, are expected to boost the demand for improved treatment strategies.

MEA is increasingly focusing on genetic counselling and risk assessment for different cancer types, thereby driving personalized healthcare. Rising consumer awareness about cancer is likely to have a positive influence on market growth. Premium pricing of drugs indicates the growing need for favorable reimbursement policies, especially in low- and middle-income countries.

No credit card required*

Publish Date: Dec 03, 2025

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer Immunotherapy Market Companies

NameProfile# EmployeesHQWebsite
Johnson & JohnsonView profile 134,400One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933www.jnj.com
Novartis AG ADRView profile 76,057Lichtstrasse 35, Basel, Switzerland, 4056www.novartis.com
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Roche Holding AGView profile 103,605Grenzacherstrasse 124, Basel, Switzerland, 4070www.roche.com
Merck & Co IncView profile 72,000126 East Lincoln Avenue, Rahway, NJ, United States, 07065www.merck.com
Bristol-Myers Squibb CoView profile 34,100Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543www.bms.com
Eli Lilly and CoView profile 43,000Lilly Corporate Center, Indianapolis, IN, United States, 46285www.lilly.com
AstraZeneca PLCView profile 89,9001 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AAwww.astrazeneca.com
Immunocore Holdings PLC ADRView profile 49792 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RYwww.immunocore.com

Middle East & Africa Cancer Immunotherapy Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cancer Immunotherapy Market Outlook will help companies and investors design strategic landscapes.


Monoclonal Antibodies was the largest segment with a revenue share of 65.95% in 2025.

Horizon Databook has segmented the Middle East & Africa cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2021 to 2033.




Rising demand for effective and cost-efficient cancer therapies is one of the major factors contributing to the growth of the cancer immunotherapy drugs market in MEA. Factors such as increase in the need for improved healthcare infrastructure and high burden of diseases, such as cancer, are expected to boost the demand for improved treatment strategies.

MEA is increasingly focusing on genetic counselling and risk assessment for different cancer types, thereby driving personalized healthcare. Rising consumer awareness about cancer is likely to have a positive influence on market growth. Premium pricing of drugs indicates the growing need for favorable reimbursement policies, especially in low- and middle-income countries.

  • Middle East & Africa Cancer Immunotherapy Market Product Outlook (Revenue, USD Million , 2021-2033)
    • Monoclonal Antibodies
    • Check Point Inhibitors
    • Oncolytic Viral Therapies and Cancer Vaccines
  • Middle East & Africa Cancer Immunotherapy Market Application Outlook (Revenue, USD Million , 2021-2033)
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Melanoma
    • Prostate Cancer
    • Head and Neck Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Other Applications
  • Middle East & Africa Cancer Immunotherapy Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Middle East & Africa Cancer Immunotherapy Market End Use Outlook (Revenue, USD Million , 2021-2033)
    • Hospitals and Clinics
    • Cancer Research Centers
    • Other End users

Reasons to subscribe to Cancer Immunotherapy Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Cancer Immunotherapy Market Outlook databook

  • Our clientele includes a mix of Cancer Immunotherapy Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Cancer Immunotherapy Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Cancer Immunotherapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Middle East Africa Cancer Immunotherapy Market, 2021-2033 (US$M)

No Access Stack Chart

MEA cancer immunotherapy market statistics, by product, 2021-2033 (US$M)

No Access Pie Chart

MEA cancer immunotherapy market statistics, by country, 2021-2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more